A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With H… (NCT07681089) | Clinical Trial Compass
RecruitingPhase 2
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
Japan4 participantsStarted 2026-09-01
Plain-language summary
This is a phase 2 study to evaluate the efficacy and safety of foscenvivint in patients with liver cirrhosis resulting from HIV/HCV co-infection in the setting of hemophilia.
Who can participate
Age range
18 Years – 79 Years
Sex
MALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients who are serum HIV-RNA positive or HIV antibody positive, with HIV-RNA maintained at \<200 copies/mL and a CD4-positive T lymphocyte count of ≥200 cells/µL at screening.
. Patients with HCV infection who have achieved sustained virologic response (SVR) at least 12 months before registration.
. Liver stiffness measurement by FibroScan of ≥12.5 kPa, corresponding to fibrosis stage F4, at screening.
. Abdominal CT showing changes in liver morphology and/or findings suggestive of portal hypertension.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is in Phase 2, which means it's still in an early stage of testing — can you help me understand how much is already known about foscenvivint's safety and whether it's been tested in people with my specific combination of HIV, HCV, and hemophilia?
2The trial is measuring something called the ALBI score as its main outcome — can you explain what that measures about my liver function and whether an improvement in that score would translate to something meaningful for how I feel or how my disease progresses?
3Since this study requires participants to have liver cirrhosis caused specifically by HIV/HCV co-infection alongside hemophilia, do my current lab results and disease history actually fit that profile, and are there any aspects of my case that might make this trial a poor match?
4Given that I have hemophilia alongside liver cirrhosis, are there any extra bleeding risks or drug interactions I should be aware of if I were to take foscenvivint, especially since cirrhosis itself can already affect how blood clots?
5Before considering this trial, would it make more sense for me to try any currently approved standard treatments for liver cirrhosis or for my HIV/HCV co-infection first, and how would enrolling in this study affect those options?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
ALBI score
Timeframe: Baseline to 24 weeks after administration